Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: A case report

Yuko Fukuda; Yoshitaka Kawa; Akiko Nonaka; Hideyuki Shiotani

doi:10.1002/ccr3.6279

Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: A case report

Clin Case Rep. 2022 Sep 2;10(9):e6279. doi: 10.1002/ccr3.6279. eCollection 2022 Sep.

Authors

Yuko Fukuda¹, Yoshitaka Kawa², Akiko Nonaka¹, Hideyuki Shiotani³

Affiliations

¹ Division of Onco-cardiology Hyogo cancer center Akashi Japan.
² Division of Respiratory Medicine Hyogo cancer center Akashi Japan.
³ Division of Health Sciences, Department of Nursing Kobe Tokiwa University Kobe Japan.

Abstract

A patient with lung cancer was administrated osimertinib. She developed symptomatic heart failure due to Takotsubo cardiomyopathy (TC). As her condition improved after discontinuing osimertinib, TC was thought to be caused by osimertinib. Reoccurrence of TC was seen after readministrating half dose of osimertinib.

Keywords: Takotsubo cardiomyopathy; heart failure; osimertinib; stress cardiomyopathy.

Publication types

Case Reports